SG Americas Securities LLC Has $5.40 Million Stock Holdings in Cencora, Inc. $COR

SG Americas Securities LLC decreased its holdings in shares of Cencora, Inc. (NYSE:COR) by 65.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,265 shares of the company’s stock after selling 33,102 shares during the quarter. SG Americas Securities LLC’s holdings in Cencora were worth $5,396,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of COR. Focus Partners Wealth increased its position in Cencora by 25.8% during the first quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock worth $1,589,000 after buying an additional 1,171 shares during the last quarter. Advisors Capital Management LLC increased its holdings in shares of Cencora by 9.3% during the 1st quarter. Advisors Capital Management LLC now owns 2,747 shares of the company’s stock valued at $764,000 after acquiring an additional 233 shares during the last quarter. Strs Ohio bought a new position in shares of Cencora in the 1st quarter valued at approximately $16,660,000. Modern Wealth Management LLC raised its stake in shares of Cencora by 16.7% in the 1st quarter. Modern Wealth Management LLC now owns 1,039 shares of the company’s stock valued at $289,000 after acquiring an additional 149 shares in the last quarter. Finally, Voya Investment Management LLC lifted its holdings in Cencora by 30.2% in the 1st quarter. Voya Investment Management LLC now owns 404,319 shares of the company’s stock worth $112,437,000 after purchasing an additional 93,673 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares in the company, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. The trade was a 12.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 20,317 shares of company stock valued at $7,009,260 in the last quarter. Corporate insiders own 10.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. JPMorgan Chase & Co. increased their price target on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. TD Cowen upped their price objective on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Mizuho raised their target price on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Robert W. Baird set a $392.00 target price on shares of Cencora in a research report on Tuesday, December 16th. Finally, Evercore ISI set a $400.00 price target on shares of Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $379.50.

Cencora Price Performance

NYSE:COR opened at $335.73 on Friday. The stock has a market cap of $65.13 billion, a P/E ratio of 42.23, a PEG ratio of 1.60 and a beta of 0.66. Cencora, Inc. has a one year low of $233.61 and a one year high of $377.54. The company has a fifty day moving average price of $349.89 and a 200 day moving average price of $318.27. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same period last year, the business posted $3.34 EPS. The business’s quarterly revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a dividend of $0.60 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio is presently 30.19%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.